COMP <GO>
BIO vs TXG // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Bio-Rad Laboratories Inc. (NYSE) VS. 10x Genomics Inc. (NASDAQ) • 15-METRIC TALLY: BIO 7
— TXG 5
■ METRIC PARITY
LAST: $372.18 (-3.18%) • MKT CAP: $9.95B
options-implied-move
—
LAST: $70.11 (-14.03%) • MKT CAP: $9.13B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. TXG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | TXG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 69.10% | -17.20 | TXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | -5.70% | +6.20 | BIO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 1.22% | +2.42 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | -9.50% | +11.30 | BIO | /operating-margins <GO> |
| Net Profit Margin | 29.40% | -6.80% | +36.20 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 5.20% | -4.50 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 25.02 | -21.43 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 45.1 | +5.00 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 24.0x | -11.40 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.95B | $9.13B | $816.7M | BIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | TXG REV | BIO GROSS % | TXG GROSS % | BIO FCF | TXG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $642.8M | 51.9% | 69.1% | $374.6M | $130.1M |
| FY 2024 | $2.57B | $610.8M | 53.7% | 67.9% | $289.6M | -$5.7M |
| FY 2023 | $2.67B | $618.7M | — | — | $254.7M | -$43.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
TXG // BETA 1.15